Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters04-06
<a href="https://laohu8.com/S/OBIO">Orchestra BioMed</a> presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy
  • Orchestra BioMed outlined two pivotal-stage cardiovascular programs, AVIM Therapy for uncontrolled hypertension in pacemaker-indicated patients and Virtue SAB for atherosclerotic artery disease.
  • AVIM Therapy BACKBEAT global pivotal trial is actively enrolling up to 500 patients across about 130 sites, with primary efficacy endpoint based on change in mean 24-hour ambulatory systolic blood pressure at 3 months.
  • Virtue SAB U.S. pivotal Virtue Trial is actively enrolling 740 coronary in-stent restenosis patients in a 1:1 randomized study versus Boston Scientific AGENT paclitaxel-coated balloon, with primary endpoint target lesion failure at 12 months.
  • Medtronic collaboration for AVIM includes $61.6 million equity investment and $20 million strategic capital commitment, with revenue share of $500-$1,600 per AVIM-enabled device.
  • Orchestra BioMed cited cash runway into Q4 2027, with $35 million in committed tranche payments from Medtronic and Ligand and up to $21 million expected from Haemonetics acquisition of Vivasure Medical.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment